Skip to main content
Erschienen in: Investigational New Drugs 6/2007

01.12.2007 | PRECLINICAL STUDIES

Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803

verfasst von: Xia Liu, Jingze Wang, Bo Sun, Yajing Zhang, Jin Zhu, Changling Li

Erschienen in: Investigational New Drugs | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Summary

Alternol is a novel compound purified from fermentation products of a microorganism in the bark of the yew tree. Because it has a similar origin as the anticancer agent paclitaxel, we hypothesized that Alternol may also have an anti-tumor effect. In this report, we chose human gastric carcinoma cell line MGC803 as the model to investigate the effects of Alternol. We evaluated cell viability using the CCK8 kit. The cell cycle distribution was analyzed by flow cytometry. AnnexinV combined with PI was performed to evaluate the apoptosis rate. The mitochondria membrane potential (MMP) was measured by a fluorescence-activated cell sorter using Rhodamin123 staining. We observed the morphological changes by immunofluorescence and Hochest33342 staining. RT-PCR and Western blot analysis were used to evaluate the changes of G2M-related regulators. Our data show that Alternol inhibited the growth of MGC803 and induced G2M arrest. Coincident with G2M arrest, phosphorylation of CDC2 on Tyr-15 was significantly elevated, which could be explained by the increase of Wee1 and decrease of CDC25C. The decreased expression of PLK1 may cause the elevation of Wee1 and CyclinB1 protein levels. Moreover, the apoptosis seemed to be secondary to G2M arrest because the elevated Caspase3, decreased MMP, and typical apoptotic morphology changes appeared after G2M arrest. These findings suggested that Alternol could inhibit the growth of MGC803 by inducing G2M arrest and apoptosis. We expected Alternol may be used as a lead compound one day and our experiments might provide some clues for further research.
Literatur
1.
Zurück zum Zitat Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRef Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRef
2.
Zurück zum Zitat Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J (1993) Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 71:594–600PubMedCrossRef Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J (1993) Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 71:594–600PubMedCrossRef
3.
Zurück zum Zitat Forastiere AA (1994) Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21:49–52PubMed Forastiere AA (1994) Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21:49–52PubMed
4.
Zurück zum Zitat Gautam A, Koshkina N (2003) Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296PubMedCrossRef Gautam A, Koshkina N (2003) Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296PubMedCrossRef
5.
Zurück zum Zitat Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J (1997) Paclitaxel as first-line treatment for metastatic breast cancer. Oncology (Huntingt) 11:19–23 Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J (1997) Paclitaxel as first-line treatment for metastatic breast cancer. Oncology (Huntingt) 11:19–23
6.
Zurück zum Zitat Gregory RE, DeLisa AF (1993) Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12:401–415PubMed Gregory RE, DeLisa AF (1993) Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12:401–415PubMed
8.
Zurück zum Zitat Booher RN, Alfa CE, Hyams JS, Beach DH (1989) The fission yeast cdc2/cdc13/suc1 protein kinase: regulation of catalytic activity and nuclear localization. Cell 58:485–497PubMedCrossRef Booher RN, Alfa CE, Hyams JS, Beach DH (1989) The fission yeast cdc2/cdc13/suc1 protein kinase: regulation of catalytic activity and nuclear localization. Cell 58:485–497PubMedCrossRef
9.
Zurück zum Zitat Gould KL, Nurse P (1989) Tyrosine phosphorylation of the fission yeast cdc2 protein kinase regulates entry into mitosis. Nature (Lond.) 342:39–45CrossRef Gould KL, Nurse P (1989) Tyrosine phosphorylation of the fission yeast cdc2 protein kinase regulates entry into mitosis. Nature (Lond.) 342:39–45CrossRef
10.
11.
Zurück zum Zitat Hashimoto O, Ueno T, Kimura R, Ohtsubo M, Nakamura T, Koga H, Torimura T, Uchida S, Yamashita K, Sata M (2003) Inhibition of proteasome-dependent degradation of Wee1 in G2-arrested Hep3 cells by TGFb1. Mol Carcinog 36:171–182PubMedCrossRef Hashimoto O, Ueno T, Kimura R, Ohtsubo M, Nakamura T, Koga H, Torimura T, Uchida S, Yamashita K, Sata M (2003) Inhibition of proteasome-dependent degradation of Wee1 in G2-arrested Hep3 cells by TGFb1. Mol Carcinog 36:171–182PubMedCrossRef
12.
Zurück zum Zitat Moon SK, Jin HS, Ko CN, Kim YS, Bae HS, Lee KS, Cho KH (2005) Inhibition of human endothelial cell proliferation by Gami–Jeonggi–San (Jiawei–Zhenqi–San) is accompanied by transcriptional up-regulation of p53 and Waf1 tumor suppressor genes. J Ethnopharmacol 100:187–192PubMedCrossRef Moon SK, Jin HS, Ko CN, Kim YS, Bae HS, Lee KS, Cho KH (2005) Inhibition of human endothelial cell proliferation by Gami–Jeonggi–San (Jiawei–Zhenqi–San) is accompanied by transcriptional up-regulation of p53 and Waf1 tumor suppressor genes. J Ethnopharmacol 100:187–192PubMedCrossRef
13.
Zurück zum Zitat Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRef Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRef
14.
Zurück zum Zitat Pavletich NP (1999) Mechanisms of Cyclin-dependent kinase regulation: structures of Cdks, their Cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287:821–828PubMedCrossRef Pavletich NP (1999) Mechanisms of Cyclin-dependent kinase regulation: structures of Cdks, their Cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287:821–828PubMedCrossRef
15.
Zurück zum Zitat Rajewsky FM, Müller R (2002) DNA repair and the cell cycle as targets in cancer therapy. In: The Cancer Handbook (Chapter 97). Nature Publishing Group, London Rajewsky FM, Müller R (2002) DNA repair and the cell cycle as targets in cancer therapy. In: The Cancer Handbook (Chapter 97). Nature Publishing Group, London
16.
17.
Zurück zum Zitat Poon RY, Chau MS, Yamashita K, Hunter T (1997) The role of CDC2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57:5168–5178PubMed Poon RY, Chau MS, Yamashita K, Hunter T (1997) The role of CDC2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57:5168–5178PubMed
18.
Zurück zum Zitat Parker LL, Piwnica-Worms H (1992) Inactivation of the p34CDC2 Cyclin B complex by the human Wee1 tyrosine kinase. Science 257:1955–1957PubMedCrossRef Parker LL, Piwnica-Worms H (1992) Inactivation of the p34CDC2 Cyclin B complex by the human Wee1 tyrosine kinase. Science 257:1955–1957PubMedCrossRef
19.
Zurück zum Zitat Graves PR (2000) The Chk1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600–5605PubMedCrossRef Graves PR (2000) The Chk1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600–5605PubMedCrossRef
20.
Zurück zum Zitat Bunz F, Dutriaux A, Lengauer C (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef Bunz F, Dutriaux A, Lengauer C (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRef
21.
Zurück zum Zitat Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, Medema RH (2000) p21 inhibits Thr161 phosphorylation of CDC2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275:30638–30643PubMedCrossRef Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, Medema RH (2000) p21 inhibits Thr161 phosphorylation of CDC2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275:30638–30643PubMedCrossRef
22.
23.
Zurück zum Zitat Winters ZE, Ongkeko WM, Harris AL, Norbury CJ (1998) p53 regulates CDC2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17:673–684PubMedCrossRef Winters ZE, Ongkeko WM, Harris AL, Norbury CJ (1998) p53 regulates CDC2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17:673–684PubMedCrossRef
24.
Zurück zum Zitat McShea A, Samuel T, Eppel JT, Galloway DA, Funk JO (2000) Identification of CIP-1-associated regulator of CyclinB (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle. J Biol Chem 275:23181–23186PubMedCrossRef McShea A, Samuel T, Eppel JT, Galloway DA, Funk JO (2000) Identification of CIP-1-associated regulator of CyclinB (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle. J Biol Chem 275:23181–23186PubMedCrossRef
25.
Zurück zum Zitat Smits VA (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2:672–676PubMedCrossRef Smits VA (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2:672–676PubMedCrossRef
26.
Zurück zum Zitat Uckun FM, Dibirdik I, Qazi S (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15:800–814PubMedCrossRef Uckun FM, Dibirdik I, Qazi S (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15:800–814PubMedCrossRef
27.
Zurück zum Zitat Zhang HS, Postigo AA, Dean DC (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16 INK4a, TGFb, and contact inhibition. Cell 97:53–61PubMedCrossRef Zhang HS, Postigo AA, Dean DC (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16 INK4a, TGFb, and contact inhibition. Cell 97:53–61PubMedCrossRef
28.
29.
Zurück zum Zitat Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitors in CAD activation and DNA degradation during apoptosis. Nature 391:96–99PubMedCrossRef Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitors in CAD activation and DNA degradation during apoptosis. Nature 391:96–99PubMedCrossRef
30.
Zurück zum Zitat Zhan Q, Fan S, Insoo B, Guillouf C, Liebermann DA, O’Connor PM, Fornace AJ (1994) Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743–3751PubMed Zhan Q, Fan S, Insoo B, Guillouf C, Liebermann DA, O’Connor PM, Fornace AJ (1994) Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743–3751PubMed
31.
Zurück zum Zitat Burger AM, Jenkins TC, Double JA, Bibby MC (1999) Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81:367–375PubMedCrossRef Burger AM, Jenkins TC, Double JA, Bibby MC (1999) Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81:367–375PubMedCrossRef
Metadaten
Titel
Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803
verfasst von
Xia Liu
Jingze Wang
Bo Sun
Yajing Zhang
Jin Zhu
Changling Li
Publikationsdatum
01.12.2007
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 6/2007
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-007-9057-4

Weitere Artikel der Ausgabe 6/2007

Investigational New Drugs 6/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.